Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

On average, insulin glargine biosimilars achieve a 26% market share after 5 years on the market. 3 Sanofi's dual pricing strategy may have slowed the market uptake of insulin biosimilars ...

Sanofi (NASDAQ:SNY) disclosed a free cash flow of €6 billion in 2024, which was brought down by slashed prices of Lantus in H1 in the US, eliminating receivables, and unfavorable exchange rate ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...